<DOC>
	<DOCNO>NCT00492544</DOCNO>
	<brief_summary>Human papillomavirus ( HPV ) infection establish necessary cause cervical cancer . GSK Biologicals develop HPV vaccine ( 580299 ) target 2 common oncogenic HPV type ( HPV-16 HPV-18 ) , find approximately 70 % cervical cancer . In previous trial , vaccine find efficacious prevention incident persistent HPV-16/18 infection associate cytological abnormality . HPV vaccination ideally perform onset sexual activity . Previous study show GSK Biologicals ' HPV vaccine 580299 safe immunogenic administer European , Asian , Latin American Australian pre-adolescents adolescent . Here , aim ass immunogenicity safety GSK Biologicals ' HPV vaccine 580299 healthy Japanese pre-adolescent adolescent female subject age 10-15 year . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Immunogenicity Safety GSK Biologicals ' HPV Vaccine 580299 Healthy Japanese Females 10-15 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator/coinvestigator believe and/or parent ( ) /legally acceptable representative ( ) comply requirement protocol enrol study . A Japanese female , include , 10 15 year age time first vaccination . Written inform consent obtain parent ( ) legally acceptable representative ( ) subject . In addition , write informed assent must obtain subject prior enrolment . Healthy subject establish medical history historydirected clinical examination enter study . All subject must negative urine pregnancy test . Subjects must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraception 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Nonabstinent premenarche subject , well subject reach menarche study , must follow precaution . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose plan study . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day first dose vaccine . Administration vaccines 8 day first dose study vaccine allow . Enrolment defer subject outside specify window . Concurrently participate another clinical study , time study period ( Month 7 ) , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Previous vaccination HPV , plan administration HPV vaccine foreseen study protocol study period ( Day 0 Month 7 ) . Previous administration component investigational vaccine . Cancer autoimmune disease treatment . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine . Hypersensitivity latex . Acute disease time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory test . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant breastfeeding subject . Subject plan become pregnant planning discontinue contraceptive precaution . Oral temperature ≥ 37.5°C/Axillary temperature ≥ 37.5°C .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Human Papillomavirus ( HPV ) vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>vaccine</keyword>
	<keyword>viral infection</keyword>
	<keyword>pre-adolescent adolescent female</keyword>
</DOC>